OnKure Therapeutics
OKUR
32 hedge funds and large institutions have $38.4M invested in OnKure Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less ownership
Funds ownership: 6.72% → 6.72% (-0%)
3% less funds holding
Funds holding: 33 → 32 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
30% less capital invested
Capital invested by funds: $55.1M → $38.4M (-$16.8M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$368K |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$133K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$88.8K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$81.1K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$66.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$490K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$95.4K |
| 3 |
RC
RBF Capital
San Francisco,
California
|
-$49K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$45K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37K |
OKUR Hedge Fund Activity: Q4 2022 in Review
32 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2022, worth a combined $38.4M — down 30% from $55.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of OKUR and 4 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 4 added.
The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $368K. The largest seller was Citadel Advisors, exiting entirely with an estimated $490K sold.
- 32 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2022, down from 33 in Q3 2022.
- Funds reported $38.4M of OnKure Therapeutics stock for Q4 2022, down 30% quarter-over-quarter.
- 4 funds opened new OnKure Therapeutics positions in Q4 2022 and 5 closed out, a net change of -1 holder.
- The largest OnKure Therapeutics buyer in Q4 2022 was ExodusPoint Capital Management, an estimated $368K added.
- The largest OnKure Therapeutics seller in Q4 2022 was Citadel Advisors, an estimated $490K sold.
Based on aggregated 13F filings for Q4 2022.